Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human

MicroRNAs (miRNAs) released into the peripheral circulation upon cellular injury have shown a promise as a new class of tissue-specific biomarkers. We were first to demonstrate that next-generation sequencing analysis of serum from human subjects with acetaminophen-induced liver injury revealed a sp...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 12; no. 5; p. e0177928
Main Authors Krauskopf, Julian, de Kok, Theo M, Schomaker, Shelli J, Gosink, Mark, Burt, Deborah A, Chandler, Patricia, Warner, Roscoe L, Johnson, Kent J, Caiment, Florian, Kleinjans, Jos C, Aubrecht, Jiri
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 17.05.2017
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:MicroRNAs (miRNAs) released into the peripheral circulation upon cellular injury have shown a promise as a new class of tissue-specific biomarkers. We were first to demonstrate that next-generation sequencing analysis of serum from human subjects with acetaminophen-induced liver injury revealed a specific signature of circulating miRNAs. We consequently hypothesized that different types of hepatic liver impairments might feature distinct signatures of circulating miRNAs and that this approach might be useful as minimally invasive diagnostic "liquid biopsies" enabling the interrogation of underlying molecular mechanisms of injury in distant tissues. Therefore we examined serum circulating miRNAs in a total of 72 serum samples from a group of 53 subjects that included patients with accidental acetaminophen overdose, hepatitis B infection, liver cirrhosis and type 2 diabetes as well as gender- and age-matched healthy subjects with no evidence of liver disease. The miRNA signatures were identified using next-generation sequencing that provided analysis for the whole miRNome, including miRNA isoforms. Compared to the healthy subjects, a total of 179 miRNAs showed altered serum levels across the diseased subjects. Although many subjects have elevated alanine aminotransferase suggesting liver impairments, we identified distinct miRNA signatures for different impairments with minimum overlap. Furthermore, the bioinformatics analysis of miRNA signatures revealed relevant molecular pathways associated with the mechanisms of toxicity and or pathogenesis of disease. Interestingly, the high proportion of miRNA isoforms present in the respective signatures indicated a new level of complexity in cellular response to stress or disease. Our study demonstrates for the first time that signatures of circulating miRNAs show specificity for liver injury phenotypes and, once validated, might become useful for diagnosis of organ pathologies as "liquid biopsies".
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conceptualization: JK TMK SJS RLW KJJ FC JCK JA.Data curation: SJS PC RLW KJJ.Formal analysis: JK FC DAB MG.Funding acquisition: JA.Investigation: JK DAB MG JA.Methodology: JK MG JA.Project administration: TMK JCK JA.Resources: TMK JCK SJS PC RLW KJJ.Software: JK FC MG.Supervision: TMK JCK JA.Validation: TMK JCK JA.Visualization: JK TMK JCK JA.Writing – original draft: JK TMK JCK JA.Writing – review & editing: JK TMK SJS MG DAB PC RLW KJJ FC JCK JA.
Competing Interests: We have the following interests: Shelli J. Schomaker, Mark Gosink, Deborah A. Burt, Patricia Chandler and Jiri Aubrecht are employed by Pfizer Inc. The project was funded by Pfizer Inc. in forms of research grants to J.C.K. (University of Maastricht) and K.J.J. (University of Michigan). There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0177928